(PharmaNewsWire.Com, September 01, 2017 ) According to the recently published report 'Hepatitis C Virus Envelope Protein E2-Pipeline Review, H2 2017'; Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 11 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Hepatitis C Virus Envelope Protein E2-E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens.
The report 'Hepatitis C Virus Envelope Protein E2-Pipeline Review, H2 2017' outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C and Genital Warts (Condylomata Acuminata).
-The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2 -The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities -The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects -The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type -The report summarizes all the dormant and discontinued pipeline projects -The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage -Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2 -Identify the use of drugs for target identification and drug repurposing -Identify potential new clients or partners in the target demographic -Develop strategic initiatives by understanding the focus areas of leading companies -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics -Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indication, H2 2017 9 Number of Products under Development by Companies, H2 2017 10 Products under Development by Companies, H2 2017 11 Number of Products under Investigation by Universities/Institutes, H2 2017 12 Products under Investigation by Universities/Institutes, H2 2017 13 Number of Products by Stage and Mechanism of Actions, H2 2017 14 Number of Products by Stage and Route of Administration, H2 2017 16 Number of Products by Stage and Molecule Type, H2 2017 18 Pipeline by Aviragen Therapeutics Inc, H2 2017 19 Pipeline by Integrated BioTherapeutics Inc, H2 2017 19 Dormant Projects, H2 2017 32 Discontinued Products, H2 2017 33
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
